Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol
- PMID: 542586
Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol
Abstract
The incidence of psychiatric abnormalities has been assessed in 38 patients with Cushing's syndrome and two with alcohol-induced pseudo-Cushing's syndrome. Twenty-six patients were examined by one of us using a standardized psychiatric interview, and this group included all those with severe to moderate psychiatric disorders. Depression was the commonest symptom: five patients (13%) were markedly or severely depressed, four (10%) were moderately depressed and 13 (32%) were mildly depressed. Four patients exhibited other, non-depressive psychiatric symptoms and only 14 (35%) were judged free from psychiatric abnormality. The first line of treatment was to reduce the circulating cortisol level either by adrenalectomy or by treatment with oral metyrapone; both patients with alcohol-induced pseudo-Cushing's syndrome were treated by alcohol withdrawal. Once the plasma cortisol level was successfully controlled, depressive symptoms were relieved in all five patients with marked or severe depression and in three of the four who were moderately depressed. Mild depressive symptoms were relieved in six of the 13 affected. It is concluded that metyrapone may be of considerable value in the management of the acute psychiatric states which may occur in Cushing's syndrome and these findings are discussed in the light of their possible pathogenesis.
Similar articles
-
Personality characteristics and quality of life in patients treated for Cushing's syndrome.Clin Endocrinol (Oxf). 2006 Mar;64(3):314-8. doi: 10.1111/j.1365-2265.2006.02462.x. Clin Endocrinol (Oxf). 2006. PMID: 16487442
-
Neuropsychiatric manifestations of patients with Cushing's syndrome. Relationship to cortisol and adrenocorticotropic hormone levels.Arch Intern Med. 1981 Feb;141(2):215-9. Arch Intern Med. 1981. PMID: 6257194
-
Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.Clin Endocrinol (Oxf). 2004 Apr;60(4):476-83. doi: 10.1111/j.1365-2265.2004.02004.x. Clin Endocrinol (Oxf). 2004. PMID: 15049963
-
Neuropsychiatric disorders in Cushing's syndrome.Neuroendocrinology. 2010;92 Suppl 1:65-70. doi: 10.1159/000314317. Epub 2010 Sep 10. Neuroendocrinology. 2010. PMID: 20829621 Review.
-
Psychiatric disorders associated with Cushing's syndrome.Psychiatr Danub. 2015 Sep;27 Suppl 1:S339-43. Psychiatr Danub. 2015. PMID: 26417792 Review.
Cited by
-
Corticosterone mediates the synaptic and behavioral effects of chronic stress at rat hippocampal temporoammonic synapses.J Neurophysiol. 2015 Sep;114(3):1713-24. doi: 10.1152/jn.00359.2015. Epub 2015 Jul 15. J Neurophysiol. 2015. PMID: 26180121 Free PMC article.
-
Dexamethasone target sites in the central nervous system and their potential relevance to mental illness.Cell Mol Neurobiol. 1993 Aug;13(4):373-86. doi: 10.1007/BF00711578. Cell Mol Neurobiol. 1993. PMID: 8252608 Free PMC article.
-
Influence of chronic stress on network states governing valence processing: Potential relevance to the risk for psychiatric illnesses.J Neuroendocrinol. 2023 Sep;35(9):e13274. doi: 10.1111/jne.13274. Epub 2023 Apr 25. J Neuroendocrinol. 2023. PMID: 37186481 Free PMC article. Review.
-
Effects of adrenocortical steroids on long-term potentiation in the limbic system: basic mechanisms and behavioral consequences.Cell Mol Neurobiol. 1993 Aug;13(4):399-414. doi: 10.1007/BF00711580. Cell Mol Neurobiol. 1993. PMID: 8252610 Free PMC article.
-
Psychiatric Symptoms in Cushing's Syndrome: A Systematic Review.Innov Clin Neurosci. 2020 Jan 1;17(1-3):30-35. Innov Clin Neurosci. 2020. PMID: 32547845 Free PMC article. Review.